Bavarian Nordic to Host First Quarter 2012 Results Conference Call

14 mei 2012 KVISTGAARD, Denmark - May 14, 2012 - Bavarian Nordic A/S (OMX: BAVA) will announce its 2012 first quarterly results on Tuesday, May 22, 2012. The company will host a conference call at 2:00 pm CET (8:00 am EDT) on the same day. Anders Hedegaard, President and CEO, will give a short presentation followed by a Q&A session. Additional participants from Bavarian Nordic are Paul Chaplin, Executive Vice President and Division President Infectious Diseases, Reiner Laus, Executive Vice President and Division President Cancer Vaccines, Ole Larsen, CFO and Rolf Sass Sørensen, Vice President Investor Relations. Dial-in numbers for the conference call are: UK: +44 (0)207 1620 177, US: +1 334 323 6203, Denmark: +45 3271 4611. Please state conference ID: 916860. For additional details please visit http://www.bavarian-nordic.com/q1 where also the accompanying presentation will be available in advance of the conference call. A recording of the conference call will be available from the company's website during the same day. Contact Rolf Sass Sørensen, Vice President Investor Relations & Communications E-mail: investor@bavarian-nordic.com Phone: +45 33 26 83 83 About Bavarian Nordic Bavarian Nordic is a vaccine-focused biotechnology company developing and producing novel vaccines for the treatment and prevention of life-threatening diseases with a large unmet medical need. The company's pipeline targets cancer and infectious diseases, and includes ten development programs. In oncology, the company's lead program is PROSTVAC®, a therapeutic vaccine candidate for advanced prostate cancer that is the subject of an ongoing pivotal Phase 3 trial and is being developed under a collaboration agreement with the National Cancer Institute. In clinical Phase 1 and Phase 2 trials, PROSTVAC® has been tested in nearly 600 patients. In infectious diseases, the company's lead program is IMVAMUNE®, a third-generation smallpox vaccine candidate that is being developed and supplied for emergency use to the U.S. Strategic National Stockpile under a contract with the U.S. Government. For more information, visit www.bavarian- nordic.com. This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Bavarian Nordic A/S via Thomson Reuters ONE [HUG#1611736]